Search clinical trials for: CYD dengue vaccine

Total 10151 results

Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (CYD00082)

Dengue Fever

Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

Dengue Virus Infection

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Human Immunodeficiency Virus | Dengue Fever | Dengue Hemorrhagic Fever

Brazil
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Peru
Sanofi Pasteur, a Sanofi Company

Completed

Efficacy and Safety of Dengue Vaccine in Healthy Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
Albert B. Sabin Vaccine Institute
Pan American Health Organization; State of Parana/Health Department of Parana; Ministry of Health of Brazil and other collaborators

Completed

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Dengue

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Mexico
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Mahidol University

Not yet recruiting

Dengue Vaccine Hesitancy Among International Travelers

Vaccine Hesitancy
Takeda

Not yet recruiting

A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia (PRIME-Q)

Dengue Fever

Malaysia
Takeda

Recruiting

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Healthy Volunteers

India
National Institute of Allergy and Infectious Diseases...

Recruiting

Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine

Response To Dengue Exposure

United States
Fundacion GESICA

Not yet recruiting

Dengue Vaccine Hesitancy and Acceptance in Endemic Regions of Argentina: Impact of Communication Strategies

Dengue
Mexican Society of Public Health
Merck Sharp & Dohme LLC

Not yet recruiting

Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico

Dengue

Mexico
University Hospital Center of Martinique
Aix Marseille Université; Observatoire Regional de la Sante Provence-Alpes-Côte... and other collaborators

Recruiting

Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean (DengueSEA)

Infectious Disease | Dengue | Vaccination | Seroprevalence

Martinique
Sanofi Pasteur, a Sanofi Company

Recruiting

Dengvaxia US Pregnancy Registry (DNG00044)

Dengue Virus Infection

Puerto Rico
AiCuris Anti-infective Cures AG
Medpace, Inc.

Recruiting

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

HSV Infection

United States, Italy, Belgium, France, United Kingdom, Germany, Switzerland, Argentina, Australia, Georgia, Greece, Mexico, Israel, Canada
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
Butantan Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)

Dengue

Brazil
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Dengue Fever

United States
University of Maryland, Baltimore
Medical Technology Enterprise Consortium (MTEC)

Completed

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

Dengue

United States
Takeda

Completed

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Healthy Volunteers

Philippines, Panama
GlaxoSmithKline

Terminated

This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia

Dengue | Dengue Vaccines

Philippines, Mexico
Takeda

Active, not recruiting

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

Dengue Fever

Mexico, United States
Butantan Institute

Active, not recruiting

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Dengue

Brazil
Takeda

Completed

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Dengue Fever

Thailand

Search clinical trials for: CYD dengue vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations